In Brief: Bristol-Myers Squibb's Droxia
Executive Summary
Bristol-Myers Squibb's Droxia: FDA's Oncologic Drugs Advisory Committee will not review hydroxyurea for reduction of pain in sickle-cell anemia on Sept. 19, at Bristol's request. The committee will meet to review Ivax' Paxene (paclitaxel) NDA beginning at 8:30 a.m. on Sept. 19...